Gionfriddo, Ilaria
Brunetti, Lorenzo
Mezzasoma, Federica
Milano, Francesca
Cardinali, Valeria
Ranieri, Roberta
Venanzi, Alessandra
Pierangeli, Sara
Vetro, Calogero
Spinozzi, Giulio http://orcid.org/0000-0002-4220-2474
Dorillo, Erica
Wu, Hsin Chieh
Berthier, Caroline
Ciurnelli, Raffaella
Griffin, Melanie J.
Jennings, Claire E.
Tiacci, Enrico
Sportoletti, Paolo http://orcid.org/0000-0002-5630-9862
Falzetti, Franca
de Thé, Hugues
Veal, Gareth J.
Martelli, Maria Paola http://orcid.org/0000-0001-9139-1729
Falini, Brunangelo http://orcid.org/0000-0002-7198-5965
Article History
Received: 30 September 2020
Revised: 19 January 2021
Accepted: 8 February 2021
First Online: 2 March 2021
Compliance with ethical standards
:
: BF licensed a patent on <i>NPM1</i> mutants (n. 102004901256449). Use of dactinomycin in acute myeloid leukemia is under patent (WO2017046108) owned by Rasna Therapeutics, Inc. BF and MPM declare honoraria from Rasna Therapeutics, Inc for scientific advisor activities. MPM declares also consultancy at Scientific Advisory Board for Abbvie, Amgen, Celgene, Janssen, Novartis, Pfizer, Jazz Pharmaceuticals, and <i>Honoraria</i> from Amgen, Celgene, Janssen, Novartis. LB declares consultancy at Scientific Advisory Board for Abbvie. CV declares consultancy at Scientific Advisory Board for Abbvie and <i>Honoraria</i> from Elma Research and Amgen. The other authors have nothing to declare.